GDC-0853 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

GDC-0853 is an orally bioavailable, selective, and reversible Bruton’s tyrosine kinase (BTK) inhibitor with IC₅₀s ranging from 2-9 nM for basophil activation, B cell receptor activation, and constitutive p-BTK activity in whole blood lysates. In rats, treatment for longer than 7 days leads to pancreatic toxicity but it does not occur in mice or dogs, even at higher doses. Formulations containing GDC-0853 were well-tolerated in Phase I clinical trials and are in additional clinical trials for rheumatoid arthritis, lupus erythematosus, lymphoma, and leukemia.

Verwenden

Fenebrutinib is a selective and reversible oral small-molecular BTK inhibitor for the treatment of rheumatoid arthritis and systemic lupus erythematosus.

GDC-0853 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

GDC-0853 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32957	60
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
career henan chemical co	+86-0371-86658258 +8613203830695	factory@coreychem.com	China	29811	58
HANGZHOU CLAP TECHNOLOGY CO.,LTD	86-571-88216897,88216896 13588875226	sales@hzclap.com	CHINA	6312	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10473	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6391	58
LEAP CHEM CO., LTD.	+86-852-30606658	market18@leapchem.com	China	24727	58
TargetMol Chemicals Inc.		support@targetmol.com	United States	38631	58
Aladdin Scientific	+1-+1(833)-552-7181	sales@aladdinsci.com	United States	52924	58
Suzhou ARTK Medchem Co., Ltd.	+86-512-68323658 +86-18168183658	sales1@artkmedchem.com	China	39004	58

---

• (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
• GDC0853
• EOS-61209
• GDC-0853 (RG7845)
• GDC-0853;GDC 0853
• FENEBRUTINIB (GDC-0853)
• FENEBRUTINIB
• CS-2241
• GDC-0853/Fenebrutinib
• 2H-Cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one, 2-[1,6-dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-
• 2-[1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4'-bipyridin]-2'-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
• inhibit,Inhibitor,GDC0853,GDC 0853,Fenebrutinib,Btk,Bruton tyrosine kinase
• 2-1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-5-(2S)-2-methyl-4-(3-oxetanyl)piperazin-1-ylpyridin-2-ylamino-6-oxo3,4'-bipyridin-2'-yl-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta4,5pyrrolo1,2-apyrazin-1(6H)-one
• (S)-2-(3'-(Hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
• 2-1,6-Dihydro-3'-(hydroxymethyl)-1-methyl-5-5-(2S)-2-methyl-4-(3-oxetanyl)piperazin-1-ylpyridin-2-ylamino-6-oxo3,4'-bipyridin-2'-yl-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta4,5pyrrolo1,2-apyrazin-1(6H)-one
• (S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one
• 1434048-34-6